Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17322761 | 1.00 | MDM2 (0.44) | MDM2MDM4TP53TLR2PTPN1 | |
| SCHEMBL29400880 | 1.00 | MDM2 (0.44) | MDM2MDM4TP53TLR2PTPN1 | |
| SCHEMBL25835417 | 0.94 | MDM2 (0.42) | MDM2MDM4TP53TLR2PTPN1 | |
| SCHEMBL29398411 | 0.90 | CASP3 (0.44) | MDM2MDM4TP53 | |
| SCHEMBL29401312 | 0.90 | CASP3 (0.44) | MDM2MDM4TP53 | |
| SCHEMBL29692843 | 0.90 | PTPN1 (0.43) | MDM2TLR2PTPN1 | |
| SCHEMBL29692939 | 0.90 | PTPN1 (0.53) | MDM2PTPN1 | |
| SCHEMBL27728772 | 0.89 | MDM4 (0.49) | MDM2MDM4TP53TLR2 | |
| SCHEMBL14436881 | 0.88 | MDM2 (0.47) | MDM2MDM4TP53TLR2 | |
| SCHEMBL29706701 | 0.88 | MDM2 (0.45) | MDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025094036-A1 | A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | PIRAMAL PHARMA LIMITED (IN) | 2025-05-08 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240175019-A1 | Skeletal Muscle Delivery Platforms and Methods of Use | Arrowhead Pharmaceuticals, Inc. | 2024-05-30 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| CN-116490214-A | Skeletal muscle delivery platform and method of use | 箭头药业股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4210763-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4210713-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4210759-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116348150-A | Lipid conjugates for delivery of therapeutic agents | 箭头药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022056277-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056269-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175019-A1 | Skeletal Muscle Delivery Platforms and Methods of Use | MUSK, MYLK2, ITGB6 | MDM2 3466/4885MDM4 4404/4885TP53 4158/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MDM2 3780/4885MDM4 4563/4885TP53 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.